Beth Seidenberg

Beth Seidenberg

Dr. Beth Seidenberg focuses on life science investing in digital health and biotech and works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining Kleiner Perkins Caufield & Byers in 2005, Beth has incubated five companies and was the founding CEO of two. She serves on the board of directors of 5 Digital Health Companies: Auxogyn, Mango Health, RedBrick Health, Practice Fusion and Spruce Health and 9 Biotech Companies: 3-V Biosciences, ARMO Biosciences, ACIR Biosciences, Breathe Technologies, Flexus and True North, including 3 publicly traded companies: Atara Bio (ATRA), Epizyme (EPZM) and Tesaro (TSRO)

Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals.

Beth grew up in New York and received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.

Outside of work, Beth loves to bike and can often be found on the weekends climbing Old La Honda Road in the hills near the office. She also enjoys golf, hiking, reading historical novels, and playing with her Cavalier King Charles Spaniel, Mattie-May. She and her husband, a retired labor lawyer, have two grown sons and a beautiful daughter-in-law.

Public / Acquired Or Merged

Companies